GalenOps prod · 0.1.0

Patients

2

Active

0

enrolled or consented

Withdrawn

0

Serious AEs

1

Open QA findings

0

Aged data queries

2

Studies & contracts

total budget 64000.00 USD

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Phase II study completed contract executed 64000 USD

Patients first 2

RefStatusConsentedStudy
P2B-031 completed 2012-09-03 A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
P2B-115 completed 2013-05-20 A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Luna participants 0

No Luna participants yet

Participants at this site have not been invited to Luna.

Safety

9 AEs · 1 serious

serious P2B-115 assessed

Grade 3 anaemia with onset in cycle 5 (2013-09-08); serious (hospitalization); assessed as related to study drug (probable); resolved 2013-09-29; action: dose reduced.

QA findings

0 open

resolved minor Protocol deviation

TUMOUR ASSESSMENT OUT OF WINDOW: CT/MRI tumour assessment performed outside the +/-7-day window of the 6-weekly schedule (subject P2B-115, 2013-06-06)

Monitoring visits 0

No visits recorded

Re-score risk to propose an on-site visit.

Payments 0

No payments on file

Milestone payments are proposed by the finance step and approved in the review queue.